Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, September 2, 2024 for the Labor Day Holiday. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations

Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations

Authors: Badve SB, Kim E, Sibia US, Borrego OT, Vara S, Damron A, Riker AI

Citation: Ochsner J. 2024 Summer;24(2):157-161. doi: 10.31486/toj.23.0119

Specialties: Genetics, Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.

Related content

Conference Presentation
BRCA1 and BRCA2 Testing When a Familial Variant is Reported
Conference Presentation
Detection of Germline and Somatic BRCA Mutations Using a 50 Gene Next Generation Sequencing Panel
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Audio Podcast
Exploring Digital Pathology and Artificial Intelligence
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care
Test FAQ
Hereditary Breast Cancer Panel
Test FAQ
BRCA Panel Plus

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.